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ABSTRACT
Vulvovaginal candidiasis is the most prevalent vaginal infection worldwide and Candida albicans is
its major agent. Vulvovaginal candidiasis is characterized by disruption of the vaginal microbiota
composition, as happens following large spectrum antibiotic usage. Recent studies support the
effectiveness of oral and local probiotic treatment for prevention of recurrent vulvovaginal
candidiasis. Saccharomyces cerevisiae is a safe yeast used as, or for, the production of ingredients for
human nutrition and health. Here, we demonstrate that vaginal administration of probiotic
Saccharomyces cerevisiae live yeast (GI) and, in part, inactivated whole yeast Saccharomyces cerevisiae
(IY), used as post-challenge therapeutics, was able to positively inﬂuence the course of vaginal
candidiasis by accelerating the clearance of the fungus. This effect was likely due to multiple
interactions of Saccharomyces cerevisiae with Candida albicans. Both live and inactivated yeasts
induced coaggregation of Candida and consequently inhibited its adherence to epithelial cells.
However, only the probiotic yeast was able to suppress some major virulence factors of Candida
albicans such as the ability to switch from yeast to mycelial form and the capacity to express several
aspartyl proteases. The effectiveness of live yeast was higher than that of inactivated whole yeast
suggesting that the synergy between mechanical effects and biological effects were dominant over
purely mechanical effects. The protection of epithelial cells to Candida-induced damage was also
observed. Overall, our data show for the ﬁrst time that Saccharomyces cerevisiae-based ingredients,
particularly the living cells, can exert beneﬁcial therapeutic effects on a widespread vaginal mucosal
infection.
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Introduction
Probiotics are live microorganisms that provide health
beneﬁts to the host when ingested in adequate
amounts. The strains most frequently used as probiotics
include: Biﬁdobacterium, Lactobacillus and Saccharomy-
ces spp.1. Compelling evidence shows that probiotics
can inﬂuence the metabolic processes of pathogens
which lead to infection, and thus confer some type of
protection against disease.2-4 In particular, it has been
well established that several pathologic processes such
as obesity and metabolic syndrome are associated with
changes in intestinal microbiota.5-7 Moreover, among
the health promoting properties such as antitumoral,
antimicrobial and hypocholesterolemic effects have
been associated with consumption of milk fermented
with probiotics.8 Additionally, fermented milk effects
have been associated with modulation of brain activity.9
Immunomodulatory activities of probiotics are impor-
tant for control of infections and have been detected in
various tissues and organs. Moreover, recent data sug-
gest that oral administration of Lactobacillus (L.) rham-
nosus inhibited allergen-induced airway inﬂammation
in an experimental system of allergic asthma.10 Further-
more some probiotics such as L. plantarum can induce
complex immune responses in dendritic cells11 which
may critically impact microbe-host interactions. Probi-
otics have also been shown to strongly inﬂuence
inﬂammatory responses. In addition, the administration
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of probiotics plays an important role in the mainte-
nance of the epithelial barrier via control of inﬂamma-
tion and cell recruitment.4
Moreover, several studies have indicated that non-via-
ble material of microbial origin positively affect human/
animal health.12
Candida albicans (C. albicans) is a commensal
organism that lives as a benign component of the
microﬂora of the human oral, gastrointestinal and vag-
inal tracts. This fungus can shift from a commensal to
a pathogenic state in response to environmental stim-
uli that trigger developmental programs that induce
the expression of virulence factors, among which the
secretion of enzymes, particularly aspartyl proteinases,
affecting host immunity, plays a fundamental role.13,14
About 3-quarters of women during their reproductive
age have at least one episode of vulvovaginal candidia-
sis (VVC) and approximately 6–8% of these subjects
undergo recurrences (3 or more per year, RVVC).15 In
this pathology, the vaginal microbiome has been sug-
gested to play an important role.16 In fact, an abnor-
mal vaginal microbiome is often associated with
symptomatic infections such as VVC. The use of wide
spectrum antibiotics leads to disruption of microﬂora and
this condition favors Candida overgrowth, speciﬁcally, col-
onization with C. albicans increases approximately from
10% to 30%.16 However, few studies support the effective-
ness of oral and local probiotics treatment with different
species of Lactobacilli for prevention or therapy of recur-
rent RVVC,17 sometimes in association with antifungal
drugs such as ﬂuconazole (FLZ).18
With the above background, the aim of this study was
to analyze the role of probiotic Saccharomyces cerevisiae
(S. cerevisiae) live yeast (GI) and inactivated whole yeast
S. cerevisiae (IY) in treating vaginal candidiasis, using a
suitable “in vivo” experimental model. Our studies also
provide some mechanistic insights into the capacity of
S. cerevisiae-based ingredients to control this experimen-
tal vaginal infection.
Results
Anticandidal activity of yeast ingredients
Previous studies show that the administration of live
yeast S. cerevisiae may be beneﬁcially used in a variety of
pathologies.4 Here we analyzed the effect of administra-
tion of S. cerevisiae live yeast (GI) and inactivated
whole yeast S. cerevisiae (IY) on the course of vaginal
candidiasis in a mouse experimental model by using bio-
luminescent C. albicans (BLI Candida).19 To this end fol-
lowing preliminary dose-ﬁndings experiments in vivo,
mice under pseudoestrus conditions were treated
intravaginally with IY (1 mg/10ml/mouse) and GI
(0.1 mg/10ml/mouse) 1 day after intravaginal challenge
with BLI Candida (10ml/mouse of 2 £ 109/ml BLI Can-
dida suspension). Saline-treated and FLZ-treated mice
served as negative and positive controls, respectively.
The results reported in Figure 1, panel A of Figure 2 and
Figure S1 show that a signiﬁcant reduction of fungal load
was observed 4 d after infection in mice treated with
both IY and GI. The effect of GI was evidenced until 12
d post-infection, while the effect of IY was only observed
until day 4. These results, obtained by measurement of
bioluminescence, were conﬁrmed by colony forming
units (CFU) recovery from vaginal washes (panel B of
Fig. 2). Noteworthy, on day C4 post-challenge, the anti-
Candida effect of IY and GI compared with FLZ (panel
B of Fig. 2).
To evaluate whether daily administration of IY and GI
could enhance the anti-Candida beneﬁcial effect of both
products, we treated the mice with the same dose above
every day starting from day C1 post challenge until day
12. The results reported in Figure 3, panel A of Figure 4
and Figure S2 show that this schedule of administration
conﬁrm that GI displayed a curative effect until day C12
post-infection, while the effect of IY was only minimally
extended to 6 d post-infection. These results were
obtained by using the measurement of bioluminescence
of the vaginal region in live animals as well as by deter-
mination of CFU from vaginal washes (panel B of
Fig. 4). In these experiments, GI compared well with
FLZ in the anticandidal activity, both on day C4 and day
C8 (panel B of Fig. 4). While the CFU level was numeri-
cally lower with IY on day C8, showing 42.5% of CFU
inhibition, the difference was not signiﬁcant.
Mechanistic insights into the observed
anticandidal activity of yeast ingredients
Aggregation and adherence
It has been shown that some microorganisms, such as
L. spp. used successfully to prevent vaginal recurrent
infections, could exert strong adhesion forces with
pathogens and bind the strains into aggregates.20 In this
line, we analyzed whether IY and GI were able to induce
C. albicans aggregation. Positive control such as L. casei21
was also used. The results reported in Table 1 show that
IY is able to self-aggregate with the maximum score
(score D 4) (according to Verdenelli M.C. et al.21). The
same maximum score was observed when IY was added
with C. albicans. Conversely, GI is unable to self-aggre-
gate, but when mixed with C. albicans, caused a consis-
tent fungal aggregation (score D 3). A representative
image is reported in Figure 5. Given that pathogen
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aggregation may compromise its capacity to adhere to
epithelium, we tested this possibility in experiments of
BLI Candida adherence to various kinds of epithelial
cells. To this end IY and GI were added to vaginal epithe-
lial cell line A-431 or cervical cancer cell line HeLa or
human vaginal epithelium for 30 min or 1 h, then BLI
Candida was added for 1 h. The bioluminescence emis-
sion of adhered BLI Candida was evaluated. Results
reported in panels A-C of Figure 6 show that treatment
with IY and GI for 30 min and 1 h signiﬁcantly pre-
vented the adherence of BLI Candida to the vaginal epi-
thelium (Fig. 6C). Regarding the effect on A-431 and
HeLa cells, a sporadic inhibition of adherence was mani-
fested. In particular, the effect of IY was observed after
30 min of pretreatment, while the effect of GI was
evident after 1 h, in both cell lines (Fig. 6A and B).
Determination of inhibition of Candida adherence was
also performed by using CFU. The results obtained
(Fig. 6 panels D–F) further suggested that Candida coag-
gregation, induced by IY and GI, is involved in adher-
ence inhibition of the fungus to vaginal epithelial cells.
The data above could be explained by competition for
C. albicans adherence exerted by the live yeast cells or
the inactivated ones. To verify this hypothesis, human
vaginal epithelium was incubated with 100 ml of FITC-
IY or FITC-GI (both 100 mg/ml) and immediately ana-
lyzed for ﬂuorescence signals. The ﬂuorescence intensity
was 3.6 £ 104 § 1168 and 3 £ 104 § 1978 for both IY
and GI, respectively (Fig. 7A). Then the cultures were
incubated for 1 h at 37C and 5% CO2. After incubation,
cells were extensively washed with phosphate-buffered
saline (PBS) and analyzed for ﬂuorescence intensity. The
results reported in Figure 7A show that ﬂuorescence sig-
nal was detected for both IY and GI, proving their ability
to adhere to the vaginal epithelium. Then, in parallel
experiment, IY and GI were added to epithelium for 1 h,
washed, then BLI Candida was added for 1 h and washed
again. A representative image of BLI Candida adherence
on vaginal epithelium is shown (Fig. 7B). Total photon
ﬂux emission from 3 different experiments is shown in
Figure 7C. These results show that both IY and GI signif-
icantly reduce BLI Candida adherence on vaginal
Figure 1. In vivo imaging of mice vaginally infected with BLI Candida and treated with a single dose of FLZ, IY or GI. Mice under pseu-
doestrus condition were treated intravaginally with 10 ml of saline, FLZ (200 mg/ml, 10 ml/mouse) or different yeast products: IY
(100 mg/ml, 10 ml/mouse) and GI (10 mg/ml, 10 ml/mouse), 1 day after challenge (2 £ 107 BLI Candida cells/10 ml/mouse). After 2, 4, 6,
8, 10 and 12 d post-infection mice were treated intravaginally with 10 ml of coelenterazine (0.5 mg/ml) and imaged in the IVIS-200TM
imaging system under anesthesia with 2.5% isoﬂurane. Total photon ﬂux emission from vaginal areas within the images (Region Of
Interest, ROI) of each mouse was quantiﬁed with Living ImageR software package.
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epithelium. Overall, the data of the above experiments
suggest for a direct competition for C. albicans adherence
by the yeasts.
Finally, we evaluated whether live Saccharomyces cells
(GI) were able to grow and multiply in the presence of
vaginal epithelium. CFU were performed after 1 h and
18 h of incubation and the results showed that under our
experimental conditions GI did not undergo signiﬁcant
proliferation neither after 1 h nor after 18 h of incubation
(not shown).
Germ-tube and hyphae formation
C. albicans undergoes a yeast to hyphae transition when
cultured in the presence of serum. In our experimental
system we mixed C. albicans in PBS plus 10% FCS with
IY and GI (both 10 mg/ml). After 2 or 4 h, germ-tube
and hyphae formation were evaluated. The results
reported in Figure 8A show that IY did neither inhibit
nor increase C. albicans transition to germ-tube and
hyphae. Conversely, a strong inhibition of germ-tube
and hyphae formation was caused by GI. Moreover,
results in Figure 8B clearly show that both IY and GI
stick to C. albicans but the inhibition of hyphae forma-
tion was observed only when Candida was incubated
with GI. Cell-free supernatant of GI cultures, but not IY,
was also able to inhibit hyphae formation suggesting that
the effect of GI could be mediated not only by the physi-
cally interaction of GI with Candida but also by the
release of soluble factors.
Figure 2. Quantiﬁcation of Total photon ﬂux emission and CFU count. Mice under pseudoestrus condition were treated intravaginally
with 10 ml of saline, FLZ (200 mg/ml, 10 ml/mouse) or different yeast products: IY (100 mg/ml, 10 ml/mouse) and GI (10 mg/ml, 10 ml/
mouse), 1 day after challenge (2 £ 107 BLI Candida cells/10 ml/mouse). After 4, 6, 8, 10 and 12 d post-infection mice were treated intra-
vaginally with 10 ml of coelenterazine (0.5 mg/ml) and imaged in the IVIS-200TM imaging system under anesthesia with 2.5% isoﬂurane.
Total photon ﬂux emission from vaginal areas within the images (Region Of Interest, ROI) of each mouse was quantiﬁed with Living
ImageR software package. Quantiﬁcation of Total photon ﬂux emission from ROI (n D 10 mice for each group from 2 different experi-
ments) was evaluated and the statistical signiﬁcance was determined with Mann-Whitney U-test (A). Values of p< 0.05 were considered
signiﬁcant (FLZ- or yeast products-treated infected mice vs saline-treated infected mice). In selected experiments, after 4 and 8 d post-
infection the CFU in vaginal washes of the mice (nD 6 mice for each group from 2 different experiments) were evaluated and the statis-
tical signiﬁcance was determined with Mann-Whitney U-test (B). Data are expressed as mean § SEM. Values of p < 0.05 were consid-
ered signiﬁcant (FLZ- or yeast products-treated infected mice vs saline-treated infected mice).
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Inhibition of SAP2 and SAP6 expression
Secretory aspartyl proteinases (Sap) have been shown
to act as major pathogenicity determinants in vaginal
candidiasis.13,14 In this pathology, clinical and experi-
mental observations revealed that a robust vaginal
inﬂammatory response is a hallmark of the pathogenic
process22 and that Sap2 and Sap6 actively participate in
inﬂammation.23 Thus we tested whether IY or GI were
able to affect the expression of these 2 Sap. To this end
C. albicans cells were incubated with BSA, a classical
SAP inducer,24 in the presence or absence of IY and
GI. After 24 h of incubation, SAP expression was evalu-
ated by quantitative (q) RT-PCR. The results reported
in Figure 9A show that SAP2 and SAP6 are, as
expected, upregulated upon BSA induction. Notewor-
thy GI, but not IY, was able to signiﬁcantly reduce the
expression of both SAP. Moreover, SAP gene expres-
sion was also evaluated in vaginal washes of mice,
treated daily with saline (10 ml/mouse), IY (100 mg/ml,
10 ml/mouse) or GI (10 mg/ml, 10 ml/mouse), after 8 d
of Candida infection. Results reported in panel B of
Figure 9 show that GI, but not IY, was able to strongly
reduce the expression of both SAP2 and SAP6 also in
an “in vivo” experimental model.
Cell damage
Finally, the capacity of both IY and GI to protect from C.
albicans-induced damage to vaginal epithelial cells or in
the vaginal epithelium was evaluated. To this end, IY and
GI were added to the vaginal epithelial cell line A-431 or
to the cervical cancer cell line HeLa or human vaginal epi-
thelium for 30 min or 1 h and then BLI Candida was
added for 18 h. The damage was measured by lactate
dehydrogenase (LDH) release as previously described.25
The results showed that by using A-431 and HeLa cells or
vaginal epithelium both IY and GI prevented the damage
induced by C. albicans (Fig. 10). Indeed, GI shows an
important and clear protective effect against C. albicans
and damage of vaginal epithelium.
Figure 3. In vivo imaging of mice vaginally infected with BLI Candida and treated daily with FLZ, IY or GI. Mice under pseudoestrus con-
dition were treated intravaginally with 10 ml of saline, FLZ (200 mg/ml, 10 ml/mouse) or different yeast products: IY (100 mg/ml, 10 ml/
mouse) and GI (10 mg/ml, 10 ml/mouse), every day starting from day C1 after challenge (2 £ 107 BLI Candida cells/10 ml/mouse). After
2, 4, 6, 8, 10 and 12 d post-infection mice were treated intravaginally with 10 ml of coelenterazine (0.5 mg/ml) and imaged in the IVIS-
200TM imaging system under anesthesia with 2.5% isoﬂurane. Total photon ﬂux emission from vaginal areas within the images (Region
Of Interest, ROI) of each mouse was quantiﬁed with Living ImageR software package.
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Discussion
Probiotics have long been considered a potential alter-
native or integrative treatment for the control of vari-
ous infectious or non-infectious pathologies. The
rationale resides on the well-known inﬂuence of the
microbiota on an organism’s homeostasis and the
potential of probiotics to reconstitute microbiota dys-
biosis or losses. For example, some probiotics mani-
fested a supportive therapeutic effect on ulcerative
colitis in an experimental animal model.26 Moreover,
probiotics are widely used as an efﬁcient adjuvant
against other gastrointestinal tract disorders such as
treatment of several types of diarrhea, both in humans
and animals. It has been also reported that live S. cere-
visiae was able to signiﬁcantly enhance the viability of
probiotic strains such as L. rhamnosus under acidic
conditions, this effect being related to pH, probiotic
and yeast concentration.27 This study also provides
Figure 4. Quantiﬁcation of Total photon ﬂux emission and CFU count. Mice under pseudoestrus condition were treated intravaginally
with 10 ml of saline, FLZ (200 mg/ml, 10 ml/mouse) or different yeast products: IY (100 mg/ml, 10 ml/mouse) and GI (10 mg/ml, 10 ml/
mouse), every day starting from dayC1 after challenge (2£ 107 BLI Candida cells/10 ml/mouse). After 4, 6, 8, 10 and 12 d post-infection
mice were treated intravaginally with 10 ml of coelenterazine (0.5 mg/ml) and imaged in the IVIS-200TM imaging system under anes-
thesia with 2.5% isoﬂurane. Total photon ﬂux emission from vaginal areas within the images (Region Of Interest, ROI) of each mouse
was quantiﬁed with Living ImageR software package. Quantiﬁcation of Total photon ﬂux emission from ROI (nD 10 mice for each group
from 2 different experiments) was evaluated and the statistical signiﬁcance was determined with Mann-Whitney U-test (A). Values of p
< 0.05 were considered signiﬁcant (FLZ- or yeast products-treated infected mice vs saline-treated infected mice). In selected experi-
ments, after 4 and 8 d post-infection the CFU in vaginal washes of the mice (n D 6 mice for each group from 2 different experiments)
were evaluated and the statistical signiﬁcance was determined with Mann-Whitney U-test (B). Data are expressed as mean § SEM. Val-
ues of p <0.05 were considered signiﬁcant (FLZ- or yeast products-treated infected mice vs saline-treated infected mice).
Table 1. Coaggregation between C. albicans (CA-6) (1 £ 109/ml)
and L. casei (3.3 McFarland) or IY and GI (both 10 mg/ml). Scores
from 0 (no aggregation) to 4 (maximum aggregation) and mean
score are shown. Data are from replicates samples of 6 different
experiments.
CA-6 L. casei IY GI CA-6 C L. casei CA-6 C IY CA-6 C GI
Exp. 1 0 0 4 0 3 4 3
Exp. 2 0 0 4 0 3 4 3
Exp. 3 0 0 4 0 3 4 3
Exp. 4 0 0 4 0 3 4 3
Exp. 5 0 0 4 0 3 4 3
Exp. 6 0 0 4 0 3 4 3
Mean score 0 0 4 0 3 4 3
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evidence that supplementation with vaginal L. rham-
nosus may be useful in discouraging growth of patho-
genic microorganisms especially after antibiotic
therapy; therefore, this treatment may be considered
for preventing vaginal infections. Moreover, a consid-
erable amount of published data indicates that the use
of non-viable microbial cells or cell components can
positively inﬂuence the host’s immune system.12
With this scientiﬁc background we focused our
attention on potential therapeutic activity of one probi-
otic i.e. live S. cerevisiae yeast (GI) and one inactivated
yeast, obtained by drum-drying (IY), against vaginal
candidiasis caused by C. albicans, using a well-known
mouse model.23 In summary, our experiments showed
that a post-challenge administration of the probiotic
yeast and, to a lesser degree, the inactivated yeast
Figure 5. Candida aggregation by FITC-L. casei, FITC-IY and FITC-GI. CFW-CA-6 (1 £ 109/ml) in 500 ml of PBS was mixed or not with
equal volume of FITC-L. casei (3.3 McFarland), FITC-IY or FITC-GI (both 10 mg/ml). Then the samples were vortexed for 10 sec and incu-
bated for 4 h at 37C under agitation. The suspensions were observed and photographed by ﬂuorescent light microscopy. Images are
representative of 3 separate experiments with similar results. (Scale Bar D 50 mm, Magniﬁcation 20x). BF D bright ﬁeld; CA-6 D blue;
L. casei, IY and GI D green.
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caused a statistically signiﬁcant increase of C. albicans
clearance from the mouse vagina, meaning a consistent
anti-infectious beneﬁt. We also observed that both S.
cerevisiae live and inactivated cells could exert some
kinds of “mechanic” such as C. albicans aggregation or
competition for space occupation on epithelial tissues,
as in fungus adherence to the vaginal epithelium. How-
ever, only the probiotic yeast could cause inhibition of
deﬁned virulence traits of C. albicans in the vaginal set-
ting such as SAP expression and yeast to hyphae transi-
tion. This suggests that the therapeutic beneﬁt is
optimally achievable only with the probiotic GI and,
importantly, the beneﬁt could be due to dampening C.
albicans virulence. Candidal vaginitis is an acute inﬂam-
matory disease that affects many women of fertile age,
with no deﬁnitive cure and with possible recurrence
causing devastation of quality of life. The local inﬂam-
matory response in the vagina is considered the crucial
event in sustaining pathologic processes.22 One of the
causes identiﬁed for clinical inﬂammation occurs in
cases of disturbed balance between the host and the col-
onizing microorganisms.28 In this study we used CD1
mouse model of vaginal candidiasis as previously
described.23,29 Indeed the outbred mice are by deﬁnition
closer to human situation. Moreover, in the most sensi-
tive inbred C57BL/6 mice, the infection is not limited
to vagina but goes upper to the uterus, causing vagina-
unrelated micro- and macroscopic damage of epithelial
cells quite well described in a previous paper of ours.30
The vaginal microbiota plays an important role in
health and disease. Lactobacillus is the dominant genus
in the vagina of healthy women whereas it is depleted
during bacterial vaginosis.31 Several studies evaluated
the effectiveness of different functional ingredients
such as probiotics in preventing RVVC. In particular,
recent results proved the beneﬁcial effect of
Figure 6. Effect of IY and GI on BLI Candida adherence and growth. A-431 cells (panels A and D), HeLa cells (panels B and E) or vaginal
epithelium (panels C and F) were incubated for 30 min or 1 h in the presence or absence of IY or GI (both 100 mg/ml). After incubation,
cells were washed 5 times, then incubated in the presence or absence of BLI Candida for 1 h. After incubation, cells were washed 5 times,
then bioluminescence emission was evaluated by luminometer after adding coelentarazine (panels A-C). Trypsin/EDTA solution (100 ml)
was added in each well, then the plates were incubated for 15 min at 37C to dissociate cells. Hence, the cellular suspension was diluted
(1/10), plated onto CHROMagar Candida and incubated at 37C for 48 h. The fungal load (the adherent BLI Candida) was quantiﬁed as
the number of CFU/ml (panels D-F). BLI Candida refers to Candida adhesion to empty wells (black bars). Data are expressed as mean §
SEM. #, p < 0.05 cells incubated with BLI Candida plus IY or GI vs cells incubated with BLI Candida alone.
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Lactobacillus spp. oral treatment in curing this type of
infection.32 Other studies evaluated the effectiveness of
probiotics in the restitution of normal vaginal micro-
ﬂora after vaginal infection including VVC.28,31
Lactobacillus spp. are an important element of vaginal
microﬂora because their production of lactic acid keeps
the vaginal pH low and prevents overgrowth of other
pathogens; thus, they are the most common probiotics
used in treating vaginal infections.31,32
Saccharomyces cerevisiae is non-pathogenic yeast
safely used for human nutrition and health, and rarely
reported to cause infection in highly predisposed, high-
risk subjects.33 The majority of studies performed with
probiotic S. cerevisiae strains have focused on gastroin-
testinal tract infections, where the microbiota unbalance
is evident.27 However, it has been recently reported that
S. cerevisiae enhances the survival and therapeutic poten-
tial of probiotic L. rhamnosus27 that is often used in
treating vaginal infection.34 In this paper we demonstrate
that intravaginal administration of S. cerevisiae-based
ingredients [living cells (GI) or dead (IY)] were able to
inﬂuence the course of vaginal candidiasis by accelerat-
ing the clearance of the fungus from the vagina. Note-
worthy, we administered IY and GI after infection, thus
the effect could be considered as a therapeutic option.
Overall, the effectiveness of GI was higher than that of
IY, and likely incorporating biological effects dominantly
over purely mechanical effects, as it happens with IY
only. In fact, GI was able to inhibit some major virulence
factors of C. albicans such as the ability to switch from
yeast to mycelial form under conditions of serum-
induced hyphal differentiation, and the capacity to
repress 2 important virulence factors, SAP2 and SAP6.
The inactivated yeast IY was able to induce C. albicans
coaggregation and exerted some protection to epithelial
cells from Candida induced damage. These effects are
probably due to mechanical effects. In fact, the inacti-
vated yeast was incapable of inﬂuencing virulence fac-
tors. This different behavior correlates with the less
effectiveness of IY with respect to GI and points out that
the probiotic yeast exerts the bigger pressure on patho-
gen populations.
We report here for the ﬁrst time that the S. cerevi-
siae-based ingredients (living cells or dead) could be
beneﬁcial in curing some vaginal mucosal infections. It
is conceivable that the different epithelial cell lines
used may produce some slight different results in
response to IY and GI, nonetheless we clearly demon-
strate that both IY and GI show competition and
interference in the adhesion of Candida to vaginal epi-
thelium, that is the most reliable indicator for interac-
tion with human vaginal epithelium. This is likely due
to multiple effects including the ability of IY and GI to
occupy the similar cellular receptors exploited by path-
ogenic Candida and, as a consequence, to inhibit
adherence. This could be related to the possibility of S.
cerevisiae and Candida sharing some external antigens
(for instance the polysaccharides mannan and glucan
Figure 7. Quantiﬁcation of FITC-IY and FITC-GI adherence on vaginal epithelium and in vitro imaging of BLI Candida adherence. 100 ml
of FITC-IY or FITC-GI (both 100 mg/ml) were added to vaginal epithelium grown in black 96-well microtiter plates with a transparent
bottom and analyzed for ﬂuorescence signals (λ D 600 nm) (pre-adherence), then incubated for 1 h at 37C plus 5% CO2. After incuba-
tion, cells were extensively washed 5 times with PBS and then analyzed again for ﬂuorescence signals (λ D 600 nm) (post-adherence)
(A). Data are expressed as mean § SEM of triplicate samples of 3 different experiments. , p < 0.05 FITC-IY-and FITC-GI-treated vaginal
epithelium vs untreated. Vaginal epithelium was grown in black 96-well microtiter plates with a transparent bottom (100 ml/well). Vagi-
nal epithelium were then incubated in the presence or absence of 100 ml of IY or GI (both 100 mg/ml) for 1 h at 37C plus 5% CO2,
extensively washed with PBS and then incubated with 100 ml of BLI Candida (1 £ 106/ml) for 1 h. After co-incubation, non-adherent BLI
Candida cells were extensively washed with PBS and 100 ml of 2 mM coelenterazine in LA buffer were added in each well. Luciferase
activity was measured by using IVIS-200TM imaging system (Xenogen Inc.) (B). Total photon ﬂux emission from each well (Region Of
Interest, ROI) was quantiﬁed with Living ImageR software package (C). Data are expressed as mean § SEM of duplicate samples of 3 dif-
ferent experiments. #, p < 0.05 IY or GI plus BLI Candida-treated vaginal epithelium vs BLI Candida-treated vaginal epithelium.
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PAMP) involved in the recognition by cellular
receptors.
Coaggregation is one of the mechanisms exerted by
probiotics to create a competitive micro-environment
around the pathogen. Moreover, a recent exhaustive
review by de Groot et al. analyzes the role of fungal adhe-
sins in modulating adhesion, aggregation, and bioﬁlm
formation.35
Both IY and GI are able to induce aggregation of Can-
dida. We do not have an explanation about the mecha-
nism that induces the coaggregation, but in a previous
paper it has been demonstrated that the coaggregation
between vaginal Staphylococci and Lactobacilli is due to
adhesive forces that occur instantly upon contact and
matured within one to two minutes.20 Thus the mecha-
nism could be similar to that described above.
The most relevant interaction of our probiotic GI live
yeast with C. albicans is the ability to inﬂuence the major
virulence factors such as hyphae transition and expres-
sion of SAP. Indeed, in our system GI (live yeast cells),
differently from IY (inactivated whole yeast), was able to
strongly inhibit germ-tube and hyphal formation under
conditions of serum-induced hyphal differentiation. It is
unclear how the live yeast inhibits hyphal growth. It may
be hypothesized that this probiotic yeast inﬂuences
hyphal transition by using, hence making unavailable to
Candida, some serum components which induce hyphal
morphogenesis by the stimulation of the cAMP-Ras1p
signaling pathway, that plays the major role in the mor-
phogenesis of C. albicans36 or by affecting the production
of C. albicans quorum sensing molecules which controls
ﬁlamentation in such pathogenic polymorphic fungi.37
In fact, competition for use of nutrients and growth stim-
ulators can be an important mechanism of probiotic
activity.
Given that morphogenesis is a key virulence factor of
C. albicans, it could be a target for the development of
antifungal drugs. Indeed, inhibiting morphogenesis has
been considered for treating candidiasis.38
Aspartyl proteases are also major virulence factors
of C. albicans because they are involved in adhesion of
the fungus and damage of epithelial cells.25 C. albicans
expresses a family of 10 SAP genes that are grouped as
follow: SAP1 to SAP3, SAP4 to SAP6, SAP7, SAP8,
SAP9 and SAP10 based upon their sequence homolo-
gies and pH activities.13 Each C. albicans Sap protein
has a distinct substrate cleavage site and pH optimum.
Sap1 to Sap3 and Sap8 have activity at lower pH val-
ues (2.5 to 5.0), whereas Sap4 to Sap6 have better
activity at higher pH values.13 Sap expression levels
and activities are regulated by cell morph-type and
environmental stimuli. It has been reported that Sap1-
Sap3 are expressed predominantly in yeast cells,
whereas Sap4-Sap6 in hyphal cells, although the in
vivo demonstration of these speciﬁc associations has
never been convincingly shown. In our hands, both in
vitro and in vivo in the CD1 vaginal candidiasis model,
we observed that both SAP2 and SAP6 genes were
expressed, consistently with some previous reports in
human infection.39 Furthermore our recent observa-
tions in C. albicans-infected CD1 mice also coherently
indicate the presence of both yeast and hyphal forms
Figure 8. Germ-tube and hyphae formation. Germ-tube and hyphae formation of C. albicans (CA-6) (1 £ 106/ml) in PBS or PBS plus
serum in the presence or absence of IY and GI (both 10 mg/ml) are shown (A). Data are reported as the percentage of germ-tube and
hyphae formation compared to control (CA-6 treated with serum) Data are the mean § SEM of 3 different experiments. #, p < 0.05 GI-
treated CA-6 plus serum vs CA-6 plus serum. Hyphae formation of CFW-CA-6 (1 £ 106/ml) in PBS or PBS plus serum in the presence or
absence of FITC-IY, FITC-GI (both 10 mg/ml) is shown (B, upper panels). Hyphae formation of CA-6 (1 £ 106/ml) in YPD or YPD plus
serum in the presence or absence of cell-free supernatants of IY and GI (both 2 mg/ml) (SIY and SGI) in YPD medium, is shown (B, lower
panels). Images are representative of 3 separate experiments with similar results. (Scale Bar D 10 mm, Magniﬁcation 20x). CA-6 D blue;
IY and GI D green
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of the fungus in the infected vagina (manuscript in
preparation).
We previously reported that Sap2 and Sap6 are exten-
sively involved in the inﬂammatory processes, and it is
well known that inﬂammation is strictly related to patho-
genesis in vaginal candidiasis.23,40,41 As a consequence,
the reduced expression of SAP2 and SAP6 GI-mediated
could partially account for the in vivo protective effect.
Noteworthy, a strong inhibition of SAP2 and SAP6
expression was observed only when GI (live yeast cells)
but not IY (inactivated yeast), was used, suggesting that
the inhibition of SAP could be related to biomolecules
present in living cells. In this study we observed that
both IY and GI are able to protect the integrity of epithe-
lial cells damaged by C. albicans. This effect was evi-
denced for both preparations, but with different
mechanisms. Indeed in this study we demonstrate that
the beneﬁcial effect of inactivated yeast of S. cerevisiae
Figure 9. Quantitative analysis of SAP2 and SAP6 genes expression. CA-6 (2 £ 106/ml) was incubated in YEPD medium or YEPD medium
plus 1% BSA in the presence or absence of IY or GI (both 10 mg/ml) for 24 h at 37C under agitation. After incubation, fungal cells were
lysed and total RNA was extracted and retro-transcribed in cDNA. C. albicans ACT1, SAP2 and SAP6 genes were detected by real-time
qPCR and cDNA quantities were reported as fold changes relative to the Candida alone. Black bars indicate CA-6 in YEPD medium with-
out BSA. Data show the mean § SEM of triplicates of 4 different experiments (A)., p < 0.05 CA-6 plus BSA vs CA-6. #, p < 0.05 GI-
treated CA-6 plus BSA vs CA-6 plus BSA. Vaginal washes from mice intravaginally infected with 2 £ 107 CA-6 cells/10 ml/mouse and
daily treated with IY (100 mg/ml) or GI (10 mg/ml), were obtained 8 d post-infection. Vaginal washes were centrifuged at 3000 rpm for
5 min, then cellular fractions were lysed and total RNA was extracted and retro-transcribed in cDNA. C. albicans ACT1, SAP2 and SAP6
genes were detected by real-time PCR and cDNA quantities were reported as 2¡DDCT relative to the Candida suspension alone. Data
show the mean § SEM of triplicates samples of 3 different mice (B)., p < 0.05 saline-treated infected mice vs CA-6 suspension used for
infection. #,p < 0.05 GI-treated infected mice vs saline-treated infected mice.
VIRULENCE 11
Figure 10. Effect of IY and GI on cellular damage induced by BLI Candida. A-431 cells (A), HeLa cells (B) or vaginal epithelium (C) were
incubated for 30 min or 1 h in the presence or absence of IY and GI (both 100 mg/ml). After incubation, cells were washed 5 times, then
incubated in the presence or absence of BLI Candida (1 £ 106/ml) for 18 h. After incubation, cellular damage induced by BLI Candida
was determined by the release of LDH. Data show the mean § SEM of triplicates samples of 3 different experiments. Values of p < 0.05
and p< 0.01 were considered signiﬁcant. #,p < 0.05 and ##,p < 0.01 cells incubated with BLI Candida plus GI or IY vs cells incubated
with BLI Candida alone.
Figure 11. IY and GI mechanism of action on vaginal epithelium. C. albicans is able to cause epithelial cell damage through its capacity
to adhere to epithelium, to switch from yeast to hyphal form and to produce aspartyl proteinases (Sap) (A). IY reduces epithelial damage
induced by C. albicans, preventing C. albicans adherence by the formation of a barrier on epithelium and by the induction of C. albicans
coaggregation (B). GI reduces epithelial damage induced by C. albicans, preventing C. albicans adherence by the formation of a barrier
on epithelium, by the induction of C. albicans coaggregation and by strongly affecting C. albicans virulence factors (C).
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(IY) was greatly due to its ability to induce coaggregation
of C. albicans and to inhibit adherence to vaginal
epithelium. The effect of live S. cerevisiae cells (GI) was
due to more complex mechanisms including inhibition of
mycelial transition and SAP expression (see mechanism of
action in Fig. 11).
These differences in the complexity of yeast ingre-
dients effects directly or indirectly strictly inﬂuence the
virulence of pathogen and integrity of epithelial cells.
In conclusion, our results support the potential of S.
cerevisiae probiotic and, likely also, inactivated yeast
product as anti-infective agents in the vagina and
encourage further studies about their capacity to prevent
and manage urogenital tract infections in females. Our
results may help devise modalities to optimize the defen-
sive properties of the vaginal microbiota, improving the
health of many women by S. cerevisiae administration.
Materials and methods
Study products
The products studied were provided by Lesaffre Human
Care (Marcq-en-Baroeul, France).
Saccharomyces cerevisiae (S. cerevisiae) live yeast (refer-
enced GI) is a proprietary, well-characterized strain of
Lesaffre, registered in the French National Collection of
Cultures of Microorganisms (CNCM) under the number
I-3856. The S. cerevisiae species is characterized by using
phenotypic (APIID32C, Biomerieux SAS) and genotypic
referenced methods (genetic ampliﬁcation and sequencing
of 26S DNA).42,43 Moreover, the strain CNCM I-3856 has
been characterized by polymerase chain reaction (PCR)
Interdelta typing techniques44 and other genetic methods
(e.g. complete genome sequencing).
Inactivated yeast of S. cerevisiae (referenced IY) is a
primary grown inactivated dried whole yeast, obtained
by drum-drying of S. cerevisiae.
The concentration of GI is 1 £ 1010 CFU/g.
Microbial strains and growth conditions
C. albicans CA1398 carrying the bioluminescence
ACT1p-gLUC59 fusion product (BLI Candida) was
used.19,45 The gLUC59 luciferase reporter has previously
been described.19 The origin and the characteristics of
the highly virulent C. albicans strain (CA-6) have previ-
ously been described.46 The cultures were maintained by
serial passages on YPD agar. The yeast cells were har-
vested by suspending a single colony in saline, washed
twice, counted in a hemocytometer and adjusted to the
desired concentration. Lactobacillus casei (L. casei) was
isolated from Italian patient and obtained from the
laboratory of mycology of the Santa Maria della Miseri-
cordia Hospital, Perugia, Italy. L. casei was grown in
Tryptic soy agar plus sheep blood.
Ethics statement
The procedures involving the animals and their care
were conducted in conformity with the national and
international laws and policies. All animal experiments
were performed in agreement with the EU Directive
2010/63, the European Convention for the Protection of
Vertebrate Animals used for Experimental and other Sci-
entiﬁc Purposes, and the National Law 116/92. The pro-
tocol was approved by Perugia University Ethics
Committee for animal care and use (Comitato Universi-
tario di Bioetica, permit number 149/2009-B). All the
animals were housed in the animal facility of the Univer-
sity of Perugia (Authorization number 34/2003A). Mice
were acclimatized for a week before starting the experi-
ments. Five to eight mice were housed in each cage and
were provided with food and water ad libitum. All efforts
were made to minimize suffering during experiments.
Mice
Female CD1 mice obtained from Charles River (Calco,
Italy) were used at 4 to 6 weeks of age. Mice were allowed
to rest for 1 week before the experiment; by that time the
animals were roughly 5 to 7 weeks old. Animals were
used under speciﬁc-pathogen free conditions that included
testing sentinels for unwanted infections; according to the
Federation of European Laboratory Animal Science Asso-
ciation standards, no infections were detected.
Infection and treatment
Mice were vaginally infected as previously described.19
Mice were maintained under pseudoestrus condition by
subcutaneous injection of 0.2 mg of estradiol valerate in
100 ml of sesame oil (Sigma-Aldrich) 5 d prior to infec-
tion and weekly until the completion of the study. Mice
anesthetized with 2.5-3.5% (v/v) isoﬂurane gas were
infected with 10 ml of 2 £ 109 cell/ml of BLI Candida.
Cell suspensions were administered from a mechanical
pipette into the vaginal lumen, close to the cervix. To
favor vaginal contact and adsorption of fungal cells, mice
were held head down for 1 min following inoculation.
Mice were then allowed to recover for 24-48 h, during
which the Candida infection was established. The intra-
vaginal treatment with FLZ (200 mg/ml, 10 ml/mouse),
IY (100 mg/ml, 10 ml/mouse) or GI (10 mg/ml, 10 ml/
mouse) was done 1 day after the challenge or every day
starting from day C1 after challenge.
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Monitoring mouse vaginal infection
At selected time points post-infection, mice were treated
with 10 ml of coelenterazine (0.5 mg/ml in 1:10 methanol:
H2O) (Synchem, OHM) in the vaginal lumen. Afterwards,
mice were imaged in the IVIS-200TM imaging system
(Xenogen Inc.) under anesthesia with 2.5% isoﬂurane.
Total photon ﬂux emission from vaginal areas within the
images (Region Of Interest, ROI) of each mouse was
quantiﬁed with Living ImageR software package.
CFU assay
In selected experiments, at day C4 and C8 post-infec-
tion, the vaginal washes were conducted with 150 ml of
saline, given in 3 separate 50 ml volumes. The ﬂuid was
serially diluted and plated on CHROMagarTM Candida
(VWR International p.b.i., Milan, Italy). CFU were then
evaluated and expressed as CFU/ml.
Cell lines and vaginal epithelium
The human A-431 vaginal epithelial cell line and the
human HeLa epithelial cervical cell line, obtained from
ATCC, were grown in DMEM plus 10% of fetal calf serum
(FCS). Human vaginal epithelium was obtained by the dif-
ferentiation of A-431 cell line as previously described.47
Adherence assay
BLI Candida adherence to cell lines was determined
using a luminometer (Tecan). A-431 and HeLa (1 £ 106/
ml) were grown for 24 h in black 96-well microtiter
plates with a transparent bottom (100 ml/well). Vaginal
epithelium was obtained by differentiation of A-431 cell
line (1 £ 106/ml) for 5 d in black 96-well microtiter
plates with a transparent bottom (100 ml/well).47 Before
stimulation, cells were incubated for 2 h in DMEM
medium without FCS. Cells were then incubated in the
presence or absence of 100 ml of IY or GI (both
100 mg/ml) for 30 min or 1 h at 37C plus 5% CO2,
extensively washed 5 times with PBS and then incu-
bated with 100 ml of BLI Candida (1 £ 106/ml) for 1 h.
After co-incubation, non-adherent BLI Candida cells
were removed by extensively rinsing 5 times with PBS
and 100 ml of 2 mM coelenterazine in luciferase assay
buffer (LA buffer) were added in each well.19 Luciferase
activity was measured using a luminometer. Biolumines-
cence representative image was performed by using IVIS-
200TM imaging system (Xenogen Inc.). Total photon ﬂux
emission from each well (Region Of Interest, ROI) was
quantiﬁed with Living ImageR software package.
Adherence was also evaluated by colony forming units
counts (CFU). To this end, the LA buffer was removed
from each well, Trypsin/EDTA solution (100 ml) was
added in each well, then the plates were incubated for
15 min at 37C plus 5% CO2 to dissociate cells. Hence,
the cellular suspension was diluted (1/10), plated onto
CHROMagar Candida and incubated at 37C for 48 h.
The fungal load (the adherent BLI Candida) was quanti-
ﬁed as the number of CFU/ml. In selected experiments,
cells were incubated with 100 ml of IY or GI (both
100 mg/ml) as above described for 1 h, then washed
5 times with PBS and treated with Trypsin/EDTA solu-
tion (100 ml) to dissociate cells, or incubated further 18 h
and then treated with Trypsin/EDTA solution (100 ml).
Hence, the cellular suspension was diluted, plated onto
Sabouraud agar and incubated at 37C for 48 h.
Fluorescent C. albicans, L. casei, IY and GI
CA-6 cells were harvested and the concentration was
adjusted to the desired concentration and labeled with Cal-
coFluor White (CFW) (0.5 mg/ml) for 30 min at RT. L.
casei (3.3 McFarland), IY and GI (10 or 100 mg/ml) were
labeled with FITC at 0.1 mg/ml in PBS at RT for 10 min.48
Adherence assay of FITC-IY and FITC-GI
Vaginal epithelium in black 96-well microtiter plates with a
transparent bottom were incubated for 2 h in DMEM
medium without FCS. 100 ml of FITC-IY or FITC-GI
(both 100 mg/ml) were added in the wells and immediately
analyzed for ﬂuorescence signals (λ D 600 nm), then cells
were incubated for 1 h at 37C plus 5% CO2. After incuba-
tion, cells were extensively washed 5 times with PBS and
then analyzed for ﬂuorescence signals (λD 600 nm).
Damage assay
A-431 and HeLa cells (both 1 £ 106/ml) were grown for
24 h in 96-well microtiter plates (100 ml/well). Vaginal
epithelium was obtained by differentiation of A-431 cell
line (1 £ 106/ml) for 5 d in 96-well microtiter plates
(100 ml/well).47 Before stimulation, cells were incubated
for 2 h in DMEM medium without FCS. Cells were then
incubated in the presence or absence of 100 ml of IY or
GI (both 100 mg/ml) for 30 min or 1 h at 37C plus 5%
CO2, extensively washed 5 times with PBS and then incu-
bated with 100 ml of BLI Candida (1 £ 106/ml) for 18 h
at 37C plus 5% CO2. After co-incubation, the epithelial
cell damage was determined by the release of LDH into
the surrounding medium. LDH was measured spectro-
photometrically at 492 nm using a Cytotoxicity Detec-
tion kit (LDH) from Pierce (Thermo Scientiﬁc, USA).
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The percentage cytotoxicity of epithelial cells infected
with BLI Candida was calculated as follows: experimen-
tal LDH release minus background cells minus back-
ground BLI Candida / mean maximal LDH release
minus background cells and compared to 100% BLI Can-
dida damage induced in each cell type.25 Considering
maximal LDH release as 100% of damage (induced by
the positive control lysis buffer), the Candida-induced
damage to A-431 cells was 46.1%, to HeLa cells 21.0%,
and to vaginal epithelium 49.2%.
Coaggregation assay
CA-6 or CFW-CA-6 (1 £ 109/ml) in 500 ml of PBS were
mixed with equal volume of L. casei or FITC-L. casei (3.3
McFarland), or with equal volume of IY, GI or FITC-IY
and FITC-GI (all 10 mg/ml). Then the samples were vor-
texed for at least 10 sec and incubated in a 24 well plates
for 4 h at 37C under agitation. The suspensions were
then observed by inversion light microscopy to evaluate
the aggregation degree and scored according to the follow-
ing scale: 0D no aggregation, 1D small aggregates com-
prising small visible clusters of yeasts, 2D aggregates
comprising larger numbers of yeasts, settling down to the
center of the well, 3D macroscopically visible clumps
comprising larger groups of yeasts which settle to the cen-
ter of the well, 4D maximum score allocated to describe a
large, macroscopically visible clump in the center of the
well.21 Moreover, each ﬂuorescent suspension was ana-
lyzed under a ﬂuorescent light microscope (Carl Zeiss).
Germ-tube and hyphae formation
500 ml of CA-6 (1 £ 106/ml) was incubated in PBS or
PBS C 10% FCS in the presence or absence of 500 ml of
IY or GI (both 10 mg/ml) in a 24 well plate for 2 or 4 h
at 37C under agitation for evaluation of germ-tube or
hyphae formation, respectively. After incubation each
suspension was diluted 1/10 and then 100 ml were used
for Gram stained smears, microscopically examined and
counted for germ-tube and hyphae formation.49 In
selected experiments, 500 ml of CFW-CA-6 (1 £ 106/ml)
was incubated in PBS or PBS C 10% FCS in the presence
or absence of 500ml of FITC-IY, FITC-GI (both 10 mg/ml).
After incubation each suspension was diluted 1/100 and
then analyzed under a ﬂuorescent light microscope (Carl
Zeiss). Moreover, 500 ml of CA-6 (1 £ 106/ml) was incu-
bated in YPD or YPD C 10% FCS in the presence or
absence or 500ml of cell-free supernatants from 24 h culture
of IY and GI (both 2 mg/ml) in YPD medium, for 4 h at
37C under agitation. After incubation each suspension
was diluted 1/100 and then analyzed under a light micro-
scope (Carl Zeiss).
Quantitative analysis of SAP2 and SAP6
gene expression
CA-6 (2 £ 106/ml) was incubated in YEPD medium or
YEPD medium plus 1% of bovine serum albumin (BSA),24
in the presence or absence of IY or GI (both 10 mg/ml) for
24 h at 37C under agitation. After incubation, fungal cells
were lysed using Trizol reagent (Life Technology). In
selected experiments, vaginal washes from mice intravagi-
nally infected with 10 ml of 2 £ 109 cell/ml of CA-6 and
daily treated with IY or GI, as described above, were
obtained 8 d post-infection. Vaginal washes were centri-
fuged at 3000 rpm for 5 min, then cellular fractions were
lysed using Trizol reagent (Life Technology).
Total RNA was extracted and retro-transcribed by
using the Moloney murine leukemia virus reverse
transcriptase reaction (M-MLV RT), as described in the
manufacturer’s instructions. cDNA concentration was
determined using a spectrophotometer. C. albicans ACT1,
SAP2 and SAP6 genes were detected by using primers
reported elsewhere.50 Real-time PCR (quantitative PCR)
was performed in 96-well PCR plates using SYBR green
(all from BioRad). For real-time PCR reaction 100 ng of
cDNA was used. All samples were measured in triplicates
and cDNA quantities reported as 2¡DDCT relative to the
Candida alone. Ampliﬁcation conditions were the same
used for ACT1 and SAP genes: 3 min at 95C, 40 cycles
of 10 sec at 95C and 30 sec at 55C. The experiments
were performed using the Eppendorf Mastercycler.
Statistical analysis
For the analysis of fungal burden by measurement of
Total photon ﬂux emission from infected vaginal areas
and CFU of vaginal washes, differences between FLZ- or
IY- and GI-treated infected mice vs saline-treated
infected mice were evaluated by Mann-Whitney U-test.
Values of p < 0.05 were considered signiﬁcant.
For the other experiments, the results reported in the
bar graphs are the mean § SEM from duplicate or tripli-
cate samples of 3-6 different experiments. Quantitative
variables were tested for normal distribution and com-
pared by means of Student’s t test. Values of p<0.05
were considered signiﬁcant.
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